Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia.
An ELISA to detect serum IgG antibody response to human papillomavirus (HPV) type 16 virus-like particles (VLPs) was evaluated in a case-control study of cervical neoplasia, nested within a prospective cohort study. Subjects included 688 controls with continued normal cytology and 152 cases with confirmed incident squamous intraepithelial lesions who were tested for DNA for a broad spectrum of HPV types at cohort and follow-up of controls, 16.6% were seropositive compared with 30.8% and 52.4% of cases with low- and high-grade lesions, respectively. Of HPV-16 DNA-negative subjects, 16.5% were seropositive. Seropositivity increased from 22.2% in subjects who were HPV-16 DNA-positive by polymerase chain reaction once only (enrollment or follow-up) to 83.3% in those who were HPV-16 DNA-positive at both time points. These data imply that serum antibody to HPV-16 VLPs is a relatively sensitive indicator of persisting cervical HPV-16 infection.
Wideroff
L
L
Environmental Epidemiology and Biostatistics Branches, National Cancer Institute, Bethesda, MD 20892-7374, USA.
Schiffman
M H
MH
Nonnenmacher
B
B
Hubbert
N
N
Kirnbauer
R
R
Greer
C E
CE
Lowy
D
D
Lorincz
A T
AT
Manos
M M
MM
Glass
A G
AG
D000914:Antibodies, Viral / Q000097:blood*; D016022:Case-Control Studies; D004279:DNA, Viral / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D016133:Polymerase Chain Reaction; D002583:Uterine Cervical Neoplasms / Q000821:virology*; D014771:Virion / Q000276:immunology*
D000914:Antibodies, Viral; D004279:DNA, Viral; D007074:Immunoglobulin G